Engineered bacterial therapy activates immune response in cancer preclinical studies
“ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination”
2025-10-08
(Press-News.org)
“ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.”
BUFFALO, NY – October 8, 2025 – A new research paper was published in Volume 16 of Oncotarget on October 6, 2025, titled “ACTM-838, a novel systemically delivered bacterial immunotherapy that enriches in solid tumors and delivers IL-15/IL-15Rα and STING payloads to engage innate and adaptive immunity in the TME and enable a durable anti-tumor immune response.”
In this study, led by first author Kyle R. Cron and corresponding author Akshata R. Udyavar, researchers from Actym Therapeutics developed a new form of bacterial immunotherapy called ACTM-838. This treatment safely delivers immune-activating proteins directly to solid tumors. The approach may offer a new option for cancer patients whose solid tumors are resistant to current immunotherapies.
Solid tumors often suppress the immune system, making it difficult for treatments like immune checkpoint inhibitors to work effectively. ACTM-838 was designed to overcome this challenge by targeting phagocytic immune cells within the tumor microenvironment (TME). Once inside the tumor, the therapy delivers two immune-stimulating components: IL-15/IL-15Rα and a modified version of STING. Both are known to activate the body’s innate and adaptive immune responses. This combination of immune-stimulating proteins helps shift the TME from immune-suppressive to immune-permissive, enabling the body’s natural defenses to fight the cancer.
“STACT is a modular, genetically engineered live attenuated S. Typhimurium bacterial platform that enables tissue-specific localization and cell-targeted delivery of large, multiplexed payloads via systemic administration.”
The study highlights how ACTM-838, built on a specially modified strain of Salmonella Typhimurium, safely targets tumors and avoids healthy tissue after intravenous injection. This targeted delivery reduces the risk of side effects while ensuring the immune-boosting agents reach their intended location. Importantly, ACTM-838 also showed significantly reduced inflammatory toxicity compared to its parent bacterial strain, which had previously presented challenges in clinical use.
In preclinical tests, ACTM-838 shrank tumors and prevented their recurrence after treatment. Mice that were cured of tumors resisted re-injection with cancer cells, suggesting the development of long-lasting immune memory. The therapy also showed strong synergy with anti-PD1 drugs, a widely used class of cancer treatments, further improving outcomes in both treatment-resistant and responsive tumor models.
Researchers also found that ACTM-838 changed the composition of immune cells within the tumor. It increased beneficial cells like cytotoxic T-cells and antigen-presenting macrophages, while reducing suppressive cell types such as regulatory T-cells and exhausted T-cells. These effects were confirmed through genetic analysis and cellular studies, pointing to a broad and coordinated immune response.
This study offers proof-of-concept that live bacterial therapy can safely and effectively deliver gene-based immune modulators directly to tumors. With ACTM-838 now being tested in a Phase I clinical trial, the findings offer a new direction for cancer treatment strategies that activate the body’s own immune system, particularly in difficult-to-treat cases where other therapies fail.
DOI: https://doi.org/10.18632/oncotarget.28769
Correspondence to: Akshata R. Udyavar – akshata.udyavar@pfizer.com
Abstract video: https://www.youtube.com/watch?v=fr5OR3tvC_I
Keywords: cancer, oncology, tumor microenvironment, bacterial vector, myeloid cells, STING, IL-15
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-10-08
The future of the electricity market may depend less on big power plants and more on everyday choices made at home. Nayeem Rahman’s dissertation at the University of Vaasa shows how consumers are gaining influence through energy flexibility, with direct implications for sustainability and costs.
For decades, the low cost of electricity provided little incentive for consumers to change their energy consumption habits. However, as prices surged due to the energy crisis that followed Russia’s invasion of Ukraine, many ...
2025-10-08
(WASHINGTON — October 8, 2025) – Most individuals living with sickle cell disease who presented to the emergency department with a pain crisis, known as vaso-occlusive crisis (VOC), were not triaged appropriately according to established national guidelines, reveals a study published today in Blood Advances. Patients triaged with a less severe category waited nearly three times as long for their first dose of pain medication when compared to individuals with sickle cell disease who were triaged appropriately.
“Pain is a significant burden in the day-to-day lives of those living with sickle cell ...
2025-10-08
ROCKVILLE, Md. — Oct. 8, 2025 — The Association for Molecular Pathology, the premier global molecular diagnostic professional society, today announced the publication of new best practice recommendations for improving how complex molecular profiling information is presented to oncologists and other healthcare providers. The manuscript, titled “Developing Consensus for a More Provider-Friendly Next-Generation Sequencing Molecular Biomarker Report: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American ...
2025-10-08
We mostly take it for granted that the position shown by our GPS is correct.
But if we are in a new city and use the map app on our phone to find our way back to the hotel, it can often look like we are jumping around from one point to another – even though we are actually walking perfectly normally on the same pavement the whole time.
“Cities are brutal for satellite navigation,” explained Ardeshir Mohamadi.
He is a doctoral fellow at the Norwegian University of Science and Technology (NTNU) ...
2025-10-08
A Northwestern University-led team of astronomers has captured the most detailed glimpse yet of a doomed star before it exploded.
Using NASA’s James Webb Space Telescope (JWST), the international team identified a supernova’s source star, or progenitor, at mid-infrared wavelengths for the first time. These observations — combined with archival images from the Hubble Space Telescope — revealed the explosion came from a massive red supergiant star, cloaked in an unexpected shroud of dust.
The discovery may help solve the decades-old mystery of why massive red supergiants rarely explode. Afterall, theoretical models predict red ...
2025-10-08
Embargoed until 7 a.m. CT/8 a.m. ET, Wednesday, Oct. 8, 2025
DALLAS, Oct. 8, 2025 — Amit Khera, M.D., FAHA, director of preventive cardiology and clinical chief of cardiology at the University of Texas (UT) Southwestern Medical Center, will receive the 2025 Chairman’s Award at the American Heart Association’s Scientific Sessions. The meeting, to be held Nov. 7-10, 2025, in New Orleans, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. Dr. Khera will receive the ...
2025-10-08
Root-knot nematodes (RKNs) are worm-like parasites of the genus Meloidogyne that are found in many parts of the world. They attack the roots of plants, causing them to wilt and eventually die. It is estimated that crops worth nearly USD 173 billion are lost every year due to RKN infestations. While chemical pesticides are effective in controlling RKNs, they also kill other microorganisms that are beneficial to plants, thereby reducing soil fertility. New, less toxic control methods are needed to prevent the loss of crops and soil fertility to RKNs.
Cellular slime mold ...
2025-10-08
Keloids are raised, overgrown scars that can develop after skin injuries or surgery, often extending beyond the original wound boundaries. For many people, keloids are more than just a cosmetic concern; they often cause distressing symptoms such as chronic pain, itching, and restricted movement. While various treatment options exist, such as surgical removal, steroid injections, and radiation, keloids are notoriously difficult to manage, with recurrence rates reaching as high as 30%.
Even after decades of study, it is still unclear why keloids grow uncontrollably, unlike hypertrophic scars. The current understanding is that an overproduction of extracellular ...
2025-10-08
(Boston)—The prevalence of Alzheimer disease (AD) is approximately two times higher in African Americans (AA) compared to White/European-ancestry (EA) individuals living in the U.S. Some of this is due to social determinants of health such as disparities in health care access and quality of education, biases in testing and higher rates of AD risk factors such as cardiovascular disease and diabetes in those who identify as African American.
Although many studies have examined differences in gene expression (measure of the amount of protein encoded by a gene) in brain tissue from AD cases and controls in EA or mixed ancestry ...
2025-10-08
In the form of a ‘nasal spray’, tiny gold particles act as carriers, delivering a treatment directly to the brain: developed by scientists at the Università Cattolica Rome campus/Fondazione Policlinico Universitario A. Gemelli IRCCS, a new nanotechnological device for the treatment and prevention of neuropsychiatric and neurodegenerative diseases. These are lithium-loaded gold nanoparticles (lithium is already in clinical use for manic-depressive syndrome, but in oral formulation, not free from side effects) to combat neuropsychiatric diseases such as bipolar disorder, neurodegenerative diseases such as Alzheimer's disease, and brain infections such as those caused ...
LAST 30 PRESS RELEASES:
[Press-News.org] Engineered bacterial therapy activates immune response in cancer preclinical studies
“ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination”
